Document:

exv10w2

Exhibit 10.2

Agreement

between

Mr. Hans Peter Hasler, Küssnacht SZ, Switzerland

(“Director”)

and

Biogen Idec International B.V., Lijnden, The Netherlands

(“Principal”)

 

	1.	 	The Principal owns the only share of Eidetica Biopharma LLC, Landis & Gyr Strasse 3, 6300
Zug, Switzerland (the “Company”).
	 
	2.	 	Upon request of the Principal, the Director agrees to continue to act as managing director of
the Company (or as chairman of the managing directors after the election of additional
managing directors) in accordance with the instructions and orders of the Principal.
Guidelines as to a Director’s role and fiduciary and legal duties are set out in the Schedule
to this Agreement.
	 
	3.	 	Unless otherwise agreed by the Parties, the Principal will give its instructions to the
Director through Michael Lytton.
	 
	4.	 	All acts of the Company and all instructions and orders given to the Director and the
management of the Company shall respect the statutes of the Company, Swiss Law and sound
commercial principles.
	 
	 	 	Should the Director refuse to take the responsibility for the execution of an instruction
although the Principal is insisting, the Director may resign as a director without any
liability for untimely resignation. In this case the Principal shall release the Director
immediately from his duties and shall give him full discharge.

 

 

2

	5.	 	The Director may act on his own without instructions and orders if urgent measures have to be
taken in the interest of the Company or the Principal and no prior consultation with the
Principal is possible.
	 
	6.	 	Provided that the Director complies with his obligations hereunder and at law, the Principal
assumes full responsibility for the activity of the Director as a managing director or
chairman of the managing directors and his management of the Company. The Principal shall
reimburse the Director for all costs and expenses and shall indemnify him for all damages
whatsoever in connection with this Agreement. The Principal shall discharge the Director from
any liability arising in connection with this Agreement. In particular, the Principal shall
exempt and release the Director of all possible liabilities or judgments which may result from
his capacity as managing director, chairman of the managing directors, founder, shareholder,
liquidator or attorney-in-fact of the Company, except if such liabilities should have been
caused by willful misconduct or gross negligence on the part of the Director.
	 
	 	 	The Principal shall indemnify the Director for all demands, damages, charges and fees
whatsoever which could be due in accordance with such liabilities. The Principal shall
reimburse the Director for all costs and expenses incurred and shall hold him harmless from
any obligations whatsoever undertaken by him in connection with this Agreement.
	 
	 	 	In particular, the Principal shall discharge the Director from any responsibility towards
the Company or third parties for measures taken by third parties without his consent.
	 
	7.	 	The Director shall receive in advance an annual director’s fee of CHF 10’000.00 gross to be
paid by the Company. The fee is subject to revision at any time by written agreement between
the parties and will in any event be reviewed either (a) if the Chief Executive Officer of the
Company changes and/or (b) if the Principal ceases to be the sole shareholder of the Company.
	 
	8.	 	The Director shall resign as a director upon request of the Principal after full discharge
has been voted by a duly convened general meeting of partners. The Director shall have the
right to resign at any point in time.
	 
	9.	 	This Agreement shall be interpreted and construed in accordance with Swiss law.
	 
	10.	 	Any dispute, controversy or claim arising out of or in relation to this contract, including
the validity, invalidity, breach or termination thereof, shall be settled by in accordance
with the Swiss Rules of International Arbitration of the Swiss Chambers of Commerce in force
on the date when the Notice of Arbitration is submitted in accordance with these Rules. The
number of arbitrators shall be one. The seat of the arbitration shall be in Zug (Switzerland).
The arbitral proceedings shall be conducted in English unless otherwise agreed by the Parties.

 

 

3

This Agreement is executed in two originals, one for each Party

	 	 	 	 	 
	                                        ,
                                              

	 	                    , April 30, 2009	 	 
	Place and date

	 	Place and date	 	 
	 
	 	 	 	 
	Principal:

	 	Director:	 	 
	 
	 	 	 	 
	/s/ Edward A. Madden
 

	 	/s/ H. P. Hasler
 

	 	 
	Edward A. Madden
	 	 	 	 
	Authorised Signatory (BVI)
	 	 	 	 

 

 

4

SCHEDULE

	I.	 	ROLE AND DUTIES
	 
	A.	 	The Board of Directors is collectively responsible for the success of the Company. The
Board’s role is to:
	 
	1.	 	provide entrepreneurial leadership of the Company within a framework of prudent and effective
controls which enable risk to be assessed and managed;
	 
	2.	 	set the Company’s strategic aims, ensure that the necessary financial and human resources are
in place for the Company to meet its objectives, and review management performance; and
	 
	3.	 	set the Company’s values and standards and ensure that its obligations to its shareholders
and others are understood and met.
	 
	B.	 	All directors must act in the way they consider, in good faith, would be most likely to
promote the success of the company for the benefit of its members as a whole. In doing so, as
a director, you must have regard (among other matters) to:
	 
	1.	 	the likely consequences of any decision in the long term;
	 
	2.	 	the interests of the Company’s employees;
	 
	3.	 	the need to foster the Company’s business relationships with suppliers, customers and others;
	 
	4.	 	the impact of the Company’s operations on the community and the environment;
	 
	5.	 	the desirability of the Company maintaining a reputation for high standards of business
conduct;
	 
	6.	 	the need to act fairly as between the members of the Company.
	 
	C.	 	In your role as a member of the Board of Directors, you shall also be required to:
	 
	1.	 	act as a legal signatory of the Company in accordance with the transaction approval and
signature authority policies of the Company in force from time. It is your responsibility to
familiarise yourself with these policies.
	 
	2.	 	constructively challenge and contribute to the development of strategy;
	 
	3.	 	scrutinise the performance of management in meeting agreed goals and objectives and monitor
the reporting of performance;
	 
	4.	 	satisfy yourself that financial information is accurate and that financial controls and
systems of risk management are robust and defensible;
	 
	5.	 	at all times comply with the By-Laws of the Company;
	 
	6.	 	diligently perform your duties and use your best endeavours to promote, protect, develop and
extend the business of the Company.

 

 

5

	II.	 	INDEPENDENT LEGAL ADVICE

In some circumstances you may consider that you need professional advice in the furtherance of your
duties as a director and it may be appropriate for you to seek advice from independent advisors at
the Company’s expense. You should consult the Company’s Legal department before engaging external
counsel.

	III.	 	OUTSIDE INTERESTS

Any potential conflicts of interest should be disclosed to the Board of Directors as soon as you
become aware of them.

	IV.	 	CONFIDENTIALITY

All information acquired during your appointment is confidential to the Company and should not be
disclosed to third parties or used for any reason other than in the interests of the Company,
either during your appointment or following termination (by whatever means), without prior
clearance from the Company.exv10w3

Exhibit 10.3

MEMORANDUM

	 	 	 
	To:

	 	Board of Directors
	From:

	 	Bob Licht
	Date:

	 	June 19, 2009
	Subject:

	 	Director Fees and Expenses

The following is a summary of the retainers and meeting fees payable to directors effective July 1,
2009.

Retainers and Fees

     Annual Retainers

	 	 	 
	$35,000

	 	Board retainer
	$20,000

	 	additional annual retainer for chair of Finance and Audit Committee
	$5,000

	 	additional annual retainer for members of Finance and Audit Committee (other than Chair)
	$15,000

	 	additional annual retainer for chairs of Corporate Governance Committee, Compensation and
Management Development Committee and Transaction Committee
	$60,000

	 	additional annual retainer for Chairman of the Board

Annual retainers will be paid in four equal quarterly installments.

     Meeting Fees

	 	 	 
	$2,500

	 	each Board meeting attended (in person or by videoconference)
	$1,500

	 	each Board meeting attended (by teleconference)
	$1,500

	 	each committee meeting attended (in person or by teleconference)

Meeting fees will be paid for attendance at formal meetings of the Board or its committees, i.e.,
those for which meeting minutes are prepared. Meeting fees will not be paid for informal
gatherings of directors.

     Special Service Fee (extraordinary)

	 	 	 
	$1,000

	 	each full day of service

The special service fee is for a full day of service, excluding services (and travel) relating to
Board or committee meetings, at the request of the Board or the Company and which involves
extensive travel by a director. It is expected that situations for which a special service fee is
due will be infrequent.

 

 

Retainers and fees will be paid shortly following the end of each calendar quarter (or, with
respect to the fourth calendar quarter, by the end of the year). Each payment will be accompanied
by a schedule explaining how the payment was calculated. Retainers are calculated on the basis of
the position held at the beginning of the calendar quarter for which payment is to be made.

Payments of retainers and fees will be reported to the IRS on Form 1099 as income, unless the
payments are made to qualifying deferred compensation accounts previously established by directors.

Expenses

The Company will reimburse directors for all reasonable out-of-pocket expenses associated with
their duties as directors, including travel to and from Board and committee meetings. The expenses
of spouses and significant others will be reimbursed when directors’ spouses and significant others
are invited to attend Company events with directors.

Expenses will be reimbursed when submitted. Expense reports, including receipts or other
supporting documentation, should be sent to the Company’s accounts payable department (attn. Drew
Gollerkeri). If you would like to fax the expense report to expedite the approval process, please
fax it to Bob Licht at 866-819-5288.

Reimbursement for directors’ expenses usually will not be reported to the IRS as income.
Reimbursement for travel expenses of others will be reported to the IRS as income, and
reimbursement for certain other expenses (for example a program that does not meet IRS guidelines)
may also be reportable as income.

Questions

Questions about retainers, fees and expenses may be addressed to the following individuals:

Bob Licht (retainers and fees, including special service fee)

Senior Vice President, Chief Corporation Counsel

Biogen Idec Inc.

14 Cambridge Center

Cambridge, MA 02142

Tel. (617) 679-3662

E-mail: bob.licht@biogenidec.com

Drew Gollerkeri (expenses)

Associate Director, Accounts Payable

Biogen Idec Inc.

14 Cambridge Center

Cambridge, MA 02142

Tel. (617) 679-3818

E-mail: drew.gollerkeri@biogenidec.com

2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00160-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00160-of-00352.parquet"}]]